Last month, the company welcomed esteemed life science professional Glenn Cross as chairman of its board.
His expertise is wide in the life sciences space, and he has worked in general management, sales, marketing, finance, distribution and manufacturing. He also has experience in human resources and product development.
“With its collaborations with world-class research institutions and its commitment to strategic integration, EZZ is well placed to further expand its business and pursue growth opportunities in the genomics area,” he added.
Mr Cross says he is excited to support the EZZ team in the next stage of its dynamic growth plans.
EZZ Life Science Holdings (ASX: EZZ) is heading into 2022 with a new chairman at the helm and plans to build on its successes of 2021 – eyeing more product growth and further international expansion.
Mr Cross has more than 40 years’ experience in life sciences and has held senior executive roles with both Australian and international companies.
Consumer health product launch
As part of the company’s life science market strategy, it launched two new products late last year.
The products comprise the EZZ Biotic EnGastro capsule and the EZZ Biotic HHP support probiotic, which aim to assist with treating helicobacter pylori and irritable bowel syndrome (IBS) by promoting healthy digestive and immune systems. EZZ acting chief executive officer Mark said the new products complement the company’s wider health and wellbeing range.
They are part of the company’s strategy to expand its product line to meet consumer-led demand in high-margin health and wellbeing segments. Product sales rise as range expands
Closing out 2021 with a new chairman and product launches follows what EZZ describes as a dramatic 12 months of growth. EZZ is focused on research and development of products using genomic technology to address four key health challenges in people: genetic longevity, human papillomavirus (HPV), helicobacter pylori and weight management.
Increasing presence in China As part of its expanded network, EZZ substantially boosted its presence in China – recording more than $10.6 million in sales through Alibaba Group’s renowned Tmall platform alone in the year ending December 2021.
While experiencing increased demand for its products, EZZ also expanded its distribution network, and developed an in-house online platform to become its main sales channel in the future. Driving the upward momentum for EZZ in 2021 was “high growth” in its core products and new offerings including: EZZ Mixed Fruit Jelly, EZZ Male Boost Stay Energizer, EZZ NMN 150,000mcg, Daily Energy & Wellbeing, EZZ Super Fruits Beverage, EZZ Iron+ Jelly, EZZ JTN Immunity Plus, EZZ L-Lysine Growth, EZZ Biotic HHP Support Probiotic, EZZ Biotic Engastro capsule, EZZ Coffee Jelly, EZZ Sweet Dream gummy and EZZ Magic gummy.